Park Ha Biological Technology Co., Ltd., a prominent player in the skincare industry, has recently undertaken significant corporate actions and financing activities that are poised to reshape its financial landscape. As an investment holding company specializing in skincare products, Park Ha operates primarily in the People’s Republic of China, with a strategic focus on both Product Sales and Franchise Service segments. The company’s product portfolio includes a diverse range of skincare solutions, from basic skin physical protection and exfoliation to advanced anti-aging treatments, all under the Park Ha brand. These products are distributed through directly operated retail stores and franchisees, ensuring a broad market reach.
In a strategic move to enhance its market position, Park Ha has entered into pivotal partnerships aimed at integrating artificial intelligence into its operations. The company collaborates with Star Plus Action (HK) Limited to develop an AI-powered skincare and health ecosystem, which is expected to significantly expand its healthcare reach. Additionally, a partnership with Cloud Factory Technology Holdings Limited is set to establish an AI-driven ecosystem for the beauty industry, further solidifying Park Ha’s commitment to innovation and technological advancement.
In early August 2026, Park Ha announced a series of corporate actions that underscore its strategic vision for growth and stability. A notable development is the approval of a reverse stock split by its shareholders and board of directors. This action, effective August 6, 2026, will reduce the number of shares outstanding while increasing the par value per share, a move often undertaken to enhance stock market perception and meet exchange listing requirements.
Concurrently, Park Ha completed a private placement on August 3, issuing ten million ordinary shares and associated warrants to non-U.S. investors. The proceeds from this placement are earmarked for general working capital and corporate purposes, providing the company with the necessary financial flexibility to pursue its strategic initiatives. In a parallel effort to incentivize its workforce, Park Ha filed a Form S-8 to register up to 2.4 million ordinary shares for its 2026 Share Incentive Plan. This plan is designed to award equity-based compensation to directors, officers, employees, and consultants, aligning their interests with the company’s long-term success.
All relevant filings for these corporate actions have been submitted to the U.S. Securities and Exchange Commission and the Cayman Islands registry. Despite these changes, Park Ha’s shares will continue to trade on Nasdaq under the symbol BYAH following the reverse stock split. As of August 4, 2026, the company’s close price stood at $0.3301, with a market capitalization of approximately $2,149,195 USD. The company’s financial metrics, including a price-earnings ratio of -0.13, reflect its current market position and future potential.
Founded in 2016 and headquartered in Wuxi, China, Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd. With its strategic partnerships and recent corporate actions, Park Ha is well-positioned to navigate the dynamic skincare industry and capitalize on emerging opportunities in the AI-driven beauty sector.
